Business Daily Media

Men's Weekly

.

APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

  • Written by PR Newswire

SHANGHAI, Dec. 24, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its product, APL-2301 (formerly known as ASN-1733; marketed as...

How to Apply for More Jobs in Less Time Using AI Automation

Most job seekers spend 11 to 14 hours per week on applications and still hear nothing back. That's not a motivation problem. That's a process proble...

Why Middle Australia Is Quietly Driving the Shift Away From Car Ownership

The narrative around changing attitudes to car ownership has long focused on Gen Z. Younger Australians are often portrayed as the generation movi...

Launchd Acquires WeAreTENZING as ANZ Creator Economy Spend Nears $1 Billion

Launchd, Australia's leading talent-first creator economy group, has acquired WeAreTENZING, one of New Zealand's most respected talent agencies, b...

Time to punch above our weight and stop shadowboxing on AI

Australia prides itself on being an innovation economy. We celebrate startups, talk about productivity, and lean into our reputation for punching ...

Colter Bay Capital Launches as Australia’s Newest Institutional Private Credit Fund

Led by seasoned capital markets veteran Mark Wang, the fund is purpose-built to serve Australia’s most productive yet chronically underserved busi...

Global Thryv voices bring a sharper lens to International Women’s Day

Thryv® (NASDAQ: THRY), ANZ’s leading AI-enabled small business marketing software platform provider, marks International Women’s Day (IWD) with a bu...